Recent News

• 08.06.2026 - Celldex Reports Second Quarter Financial Results and Provides Corporate Update
• 07.21.2026 - Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
• 07.15.2026 - Celldex Announces Planned Transition of Chief Financial Officer
• 06.14.2026 - Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
• 06.14.2026 - Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
• 06.10.2026 - Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
• 05.07.2026 - Celldex Reports First Quarter Financial Results and Provides Corporate Update
• 04.13.2026 - Celldex to Present at Upcoming Investor Conference
• 04.06.2026 - Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
• 04.02.2026 - Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Recent Filings

• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 07.15.2026 - 8-K Current report
• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities